1. Articles from Emma Court

    1-4 of 4
    1. WeWork Board Members are Talking About Ousting CEO Adam Neumann Amid IPO Turmoil

      WeWork Board Members are Talking About Ousting CEO Adam Neumann Amid IPO Turmoil
      • Some board members at coworking startup WeWork aim to push out CEO Adam Neumann, according to a report from the Wall Street Journal.
      • The board could meet this week and might discuss Neumann becoming WeWork's nonexecutive chairman, the Journal reported.
      • According to the report, it was unclear how all of the company's seven directors — a list that includes Adam Neumann himself — have sided...
      Read Full Article
    2. Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting

      Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting
      • Opposition to pharmaceutical company Bristol-Myers Squibb's $74 billion acquisition of Celgene is growing.

      • The deal is facing pushback from Bristol-Myers' second-largest shareholder, the investment firm Wellington Management, as well as from activist investor Starboard Value.

      • If Bristol-Myers shareholders oppose the deal at an April meeting, the pharma giant may owe Celgene $2.2 billion and other fees...

      Read Full Article
    3. David Tepper’s Appaloosa Hedge Fund just Slammed the Leadership of $50 Billion Drugmaker Allergan, and is Calling for Change

      David Tepper’s Appaloosa Hedge Fund just Slammed the Leadership of $50 Billion Drugmaker Allergan, and is Calling for Change
      • Billionaire David Tepper's Appaloosa LP made a strongly-worded call for change to drugmaker Allergan's board leadership structure on Tuesday.
      • Appaloosa wants Allergan's board to separate the role of chairman and CEO, which today are both held by Allergan's Brent Saunders.
      • In a Tuesday letter, Appaloosa slammed Allergan's executive decision-making, "the record for which has been fraught with ill-considered initiatives and self-inflicted wounds for several years now."..
      Read Full Article
    4. Tenet Shares Surge 15% on Board Member Exits but don’t Expect it to ‘go gentle into that good night’

      Tenet Shares Surge 15% on Board Member Exits but don’t Expect it to ‘go gentle into that good night’

      Tenet Healthcare Corp. may be poised for a proxy fight with Glenview Capital Management LLC, the company’s largest institutional shareholder, after two board members representing Glenview resigned their positions. But Tenet THC, +14.60% “may not go gentle into that good night,” said Mizuho analyst Sheryl Skolnick, referencing a well-known Dylan Thomas poem about death. To “be clear: we expect Glenview to mount a campaign to change THC’s direction, potentially even to change management...

      Read Full Article
    1-4 of 4
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Topics in the News

    1. (8 articles) Board of Directors
    2. (8 articles) Board
    3. (3 articles) Wall Street
    4. (3 articles) Board of Directors
    5. (3 articles) Investors
    6. (3 articles) Shareholder
    7. (2 articles) Management
    8. (2 articles) CEO
    9. (2 articles) Nasdaq
    10. (2 articles) Management
    11. (2 articles) stock options
    12. (2 articles) Investor
    13. (2 articles) COVID-19
    14. (2 articles) Companies
    15. (1 articles) Leadership
    16. (1 articles) Bloomberg
    17. (1 articles) hostile takeover
    18. (1 articles) Bristol-Myers Squibb
    19. (1 articles) stake
    20. (1 articles) Proxy Fight
  3. Popular Articles

  4. Picture Gallery

    Tenet Shares Surge 15% on Board Member Exits but don’t Expect it to ‘go gentle into that good night’ David Tepper’s Appaloosa Hedge Fund just Slammed the Leadership of $50 Billion Drugmaker Allergan, and is Calling for Change Bristol-Myers Squibb has $2.2 Billion at Stake if its Deal to Acquire Celgene Falls Apart, and Opposition is Mounting WeWork Board Members are Talking About Ousting CEO Adam Neumann Amid IPO Turmoil Japan Kept Activist Investor in Limbo Over Key Toshiba Vote, Sources Say 5 Steps for Building Better Board Engagement ESG Takes Center Stage Amid Economic Crisis and Social Unrest Fortive Announces Appointment of Sharmistha Dubey to the Board Pulse Biosciences, Inc. Appoints Richard Van Den Broek to Board of Directors Angelique Brunner Joins Cushman & Wakefield Board of Directors FibroGen Announces New Appointments to its Board of Directors ‘Stakeholder’ Capitalism Seems Mostly for Show